HUE044960T2 - Légúti szincíciális vírus okozta fertõzések kezelésében hasznos pirrolo-[1,2,F][1,2,4]triazinok - Google Patents

Légúti szincíciális vírus okozta fertõzések kezelésében hasznos pirrolo-[1,2,F][1,2,4]triazinok

Info

Publication number
HUE044960T2
HUE044960T2 HUE14806123A HUE14806123A HUE044960T2 HU E044960 T2 HUE044960 T2 HU E044960T2 HU E14806123 A HUE14806123 A HU E14806123A HU E14806123 A HUE14806123 A HU E14806123A HU E044960 T2 HUE044960 T2 HU E044960T2
Authority
HU
Hungary
Prior art keywords
pyrrolo
infections
treatment
respiratory syncytial
triazines useful
Prior art date
Application number
HUE14806123A
Other languages
English (en)
Hungarian (hu)
Inventor
Michael O'neil Clarke
Edward Doerffler
Richard Mackman
Dustin Siegel
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52003049&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE044960(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of HUE044960T2 publication Critical patent/HUE044960T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE14806123A 2013-11-11 2014-11-06 Légúti szincíciális vírus okozta fertõzések kezelésében hasznos pirrolo-[1,2,F][1,2,4]triazinok HUE044960T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361902544P 2013-11-11 2013-11-11

Publications (1)

Publication Number Publication Date
HUE044960T2 true HUE044960T2 (hu) 2019-12-30

Family

ID=52003049

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE14806123A HUE044960T2 (hu) 2013-11-11 2014-11-06 Légúti szincíciális vírus okozta fertõzések kezelésében hasznos pirrolo-[1,2,F][1,2,4]triazinok
HUE18209267A HUE059683T2 (hu) 2013-11-11 2014-11-06 Légúti óriássejtes vírus okozta fertõzések kezelésére alkalmazható pirrolo[1,2-F][1,2,4]triazinok

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE18209267A HUE059683T2 (hu) 2013-11-11 2014-11-06 Légúti óriássejtes vírus okozta fertõzések kezelésére alkalmazható pirrolo[1,2-F][1,2,4]triazinok

Country Status (36)

Country Link
US (5) US9388208B2 (https=)
EP (3) EP4122932A1 (https=)
JP (8) JP6234571B2 (https=)
KR (4) KR102243724B1 (https=)
CN (3) CN114085243B (https=)
AP (1) AP2016009186A0 (https=)
AU (5) AU2014346665A1 (https=)
BR (1) BR112016010261B1 (https=)
CA (1) CA2928674C (https=)
CL (1) CL2016001120A1 (https=)
CR (1) CR20160220A (https=)
CU (1) CU20160065A7 (https=)
CY (2) CY1121948T1 (https=)
DK (2) DK3505173T3 (https=)
DO (1) DOP2016000107A (https=)
EA (2) EA039734B1 (https=)
ES (2) ES2743619T3 (https=)
GT (1) GT201600086A (https=)
HR (2) HRP20220920T1 (https=)
HU (2) HUE044960T2 (https=)
IL (1) IL245324B (https=)
LT (2) LT3068405T (https=)
MD (1) MD4596C1 (https=)
MX (2) MX376186B (https=)
MY (2) MY197933A (https=)
NZ (1) NZ719592A (https=)
PE (1) PE20160670A1 (https=)
PH (1) PH12016500867A1 (https=)
PL (2) PL3068405T3 (https=)
PT (2) PT3068405T (https=)
SG (1) SG11201603427XA (https=)
SI (2) SI3505173T1 (https=)
TR (1) TR201910961T4 (https=)
UA (1) UA119050C2 (https=)
WO (1) WO2015069939A1 (https=)
ZA (1) ZA201603123B (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
AU2015320511B2 (en) 2014-09-26 2020-11-12 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of Respiratory Syncytial Virus RNA replication
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ N4-ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
MX391226B (es) * 2015-09-23 2025-03-21 Merck Sharp & Dohme Llc Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
AU2017231824B2 (en) 2016-03-09 2021-07-01 Alios Biopharma, Inc. Acyclic antivirals
US10682368B2 (en) 2017-03-14 2020-06-16 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CA3059777C (en) 2017-05-01 2023-02-21 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
CA3075950A1 (en) * 2017-09-18 2019-03-21 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN109748921B (zh) * 2017-11-03 2022-03-22 中国科学院上海药物研究所 N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CN108787177B (zh) * 2018-08-07 2024-03-15 中南大学 淤浆法制备黄原酸盐的方法及系统
WO2020232194A1 (en) * 2019-05-14 2020-11-19 The Regents Of The University Of Michigan Methods for glycosylation
JP2023512656A (ja) 2020-01-27 2023-03-28 ギリアード サイエンシーズ, インコーポレイテッド SARS CoV-2感染を治療するための方法
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI791193B (zh) 2020-02-18 2023-02-01 美商基利科學股份有限公司 抗病毒化合物
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
CN111187269A (zh) * 2020-02-27 2020-05-22 江苏阿尔法药业有限公司 一种瑞德西韦中间体的合成方法
CN113336758B (zh) * 2020-03-03 2022-08-19 北京桦冠医药科技有限公司 化合物7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的一种新合成方法
CN111233870A (zh) * 2020-03-11 2020-06-05 中国科学技术大学 用于快速制备瑞德西韦药物中间体的方法
KR20220153619A (ko) 2020-03-12 2022-11-18 길리애드 사이언시즈, 인코포레이티드 1'-시아노 뉴클레오사이드의 제조 방법
CA3172483A1 (en) 2020-04-06 2021-10-14 Scott Ellis Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CN112778310B (zh) 2020-04-20 2025-05-30 中国科学院上海药物研究所 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
CN113527303B (zh) * 2020-04-21 2022-06-10 浙江工业大学 一种瑞德西韦母核中间体的制备工艺
CN111440176B (zh) * 2020-04-28 2022-04-26 江苏大学 金属配合物促进的瑞德西韦中间体的合成方法
TW202203941A (zh) 2020-05-29 2022-02-01 美商基利科學股份有限公司 瑞德西韋之治療方法
CN111620903A (zh) * 2020-06-17 2020-09-04 安徽贝克联合制药有限公司 C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
PE20230618A1 (es) 2020-06-24 2023-04-14 Gilead Sciences Inc Analogos de nucleosido de 1'-ciano y usos de los mismos
CN111732618A (zh) * 2020-07-03 2020-10-02 镇江巨杰新材料技术研发中心(有限合伙) 瑞德西韦关键片段的合成方法
CN111793101B (zh) 2020-07-17 2022-09-30 四川大学 C-核苷化合物的合成方法
EP4192839B1 (en) 2020-08-06 2025-10-01 Richter Gedeon Nyrt. Remdesivir intermediates
IL300412A (en) 2020-08-24 2023-04-01 Gilead Sciences Inc Phospholipid compounds and their uses
IL300453A (en) 2020-08-27 2023-04-01 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS
TW202344257A (zh) * 2020-10-16 2023-11-16 美商基利科學股份有限公司 磷脂化合物及其用途
CN113880846B (zh) * 2020-12-31 2022-10-14 山东诚汇双达药业有限公司 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4389750A4 (en) 2021-08-20 2025-10-01 Shionogi & Co NUCLEOSIDE DERIVATIVES AND THEIR PRODRUGS HAVING VIRAL GROWTH INHIBITORY ACTION
KR20240154647A (ko) 2022-03-02 2024-10-25 길리애드 사이언시즈, 인코포레이티드 바이러스성 감염 치료를 위한 화합물 및 방법
KR20240155326A (ko) * 2022-03-03 2024-10-28 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물 및 이의 제조와 사용 방법
JP2025508941A (ja) * 2022-03-03 2025-04-10 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス化合物並びにその作製及び使用方法
US12357577B1 (en) 2024-02-02 2025-07-15 Gilead Sciences, Inc. Pharmaceutical formulations and uses thereof
WO2024173458A1 (en) 2023-02-16 2024-08-22 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
US20250090537A1 (en) 2023-08-31 2025-03-20 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
AU2024330988A1 (en) 2023-08-31 2026-02-19 Gilead Sciences, Inc. Antiviral compounds and methods of making and using the same
US20250109157A1 (en) 2023-09-28 2025-04-03 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3565070A (en) 1969-02-28 1971-02-23 Riker Laboratories Inc Inhalation actuable aerosol dispenser
FR2224175B1 (https=) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
SE438261B (sv) 1981-07-08 1985-04-15 Draco Ab Anvendning i dosinhalator av ett perforerat membran
US4805811A (en) 1985-03-29 1989-02-21 Aktiebolaget Draco Dosage device
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US4955371A (en) 1989-05-08 1990-09-11 Transtech Scientific, Inc. Disposable inhalation activated, aerosol device for pulmonary medicine
DE69230613T2 (de) 1991-07-02 2000-12-28 Inhale Inc Verfahren und vorrichtung zum abgeben von medikamenten in aerosolform
US5261538A (en) 1992-04-21 1993-11-16 Glaxo Inc. Aerosol testing method
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
US5388572A (en) 1993-10-26 1995-02-14 Tenax Corporation (A Connecticut Corp.) Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
US5622163A (en) 1994-11-29 1997-04-22 Iep Group, Inc. Counter for fluid dispensers
US5544647A (en) 1994-11-29 1996-08-13 Iep Group, Inc. Metered dose inhalator
US6116234A (en) 1999-02-01 2000-09-12 Iep Pharmaceutical Devices Inc. Metered dose inhaler agitator
WO2002032920A2 (en) * 2000-10-18 2002-04-25 Pharmasset Limited Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
EP1435974A4 (en) 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
AR046959A1 (es) * 2003-12-18 2006-01-04 Tibotec Pharm Ltd Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio
MX2009007333A (es) 2007-01-12 2009-08-31 Biocryst Pharm Inc Analogos de nucleosidos antivirales.
HRP20120914T1 (hr) 2007-05-10 2012-12-31 Biocryst Pharmaceuticals, Inc. Spojevi tetrahidrofuro[3,4-d]dioksolana, namijenjeni upotrebi u lijeäśenju virusnih infekcija i raka
ATE515861T1 (de) 2007-07-25 2011-07-15 Nokia Siemens Networks Oy Verfahren zur adressierung von ethernetströmen mit strukturierter gpon-gem-port-id
HUE025528T2 (en) * 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) * 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
US8455451B2 (en) * 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
MX2012003126A (es) * 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
CN102596958A (zh) 2009-09-21 2012-07-18 吉里德科学公司 用于抗病毒治疗的2’-氟代carba-核苷类似物
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之2’-氟取代之碳-核苷類似物
BR112013008017A2 (pt) * 2010-09-20 2016-06-14 Gilead Sciences Inc análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral
US20130273005A1 (en) * 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US20130143835A1 (en) * 2011-12-05 2013-06-06 Medivir Ab HCV Polymerase Inhibitors
SG10201913554YA (en) * 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
MD4496C1 (ro) * 2012-03-13 2018-02-28 Gilead Sciences, Inc. Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
EP2906579B1 (en) 2012-10-08 2018-04-18 Idenix Pharmaceuticals LLC. 2'-chloro nucleoside analogs for hcv infection
TWI582077B (zh) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 作爲IL-12、IL-23及/或IFNα反應調節劑之經烷基-醯胺取代之吡啶化合物
UA119050C2 (uk) * 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ

Also Published As

Publication number Publication date
SI3505173T1 (sl) 2022-09-30
ES2743619T3 (es) 2020-02-20
US9701682B2 (en) 2017-07-11
DK3068405T3 (da) 2019-07-29
EP3068405B1 (en) 2019-05-01
AU2023202506B2 (en) 2025-01-23
WO2015069939A1 (en) 2015-05-14
EA039734B1 (ru) 2022-03-04
CU20160065A7 (es) 2016-09-30
MD4596C1 (ro) 2019-05-31
ES2926155T3 (es) 2022-10-24
JP7054394B2 (ja) 2022-04-13
KR102243724B1 (ko) 2021-04-23
PE20160670A1 (es) 2016-07-10
CY1121948T1 (el) 2020-10-14
CN114085243B (zh) 2024-04-26
IL245324A0 (en) 2016-06-30
EA201690978A1 (ru) 2016-09-30
JP2021046413A (ja) 2021-03-25
JP2017502925A (ja) 2017-01-26
AP2016009186A0 (en) 2016-04-30
CN110003215A (zh) 2019-07-12
PH12016500867A1 (en) 2016-06-20
GT201600086A (es) 2018-01-17
KR20200057103A (ko) 2020-05-25
AU2021201554A1 (en) 2021-04-01
MX376186B (es) 2025-03-07
PL3068405T3 (pl) 2019-10-31
JP2024041986A (ja) 2024-03-27
AU2014346665A1 (en) 2016-05-19
CY1125559T1 (el) 2026-02-25
CL2016001120A1 (es) 2017-05-05
CN105899216B (zh) 2019-03-05
JP6393380B2 (ja) 2018-09-19
AU2021201554B2 (en) 2023-02-02
CN105899216A (zh) 2016-08-24
US20150133395A1 (en) 2015-05-14
HUE059683T2 (hu) 2022-12-28
EP3505173B1 (en) 2022-07-06
CN114085243A (zh) 2022-02-25
CR20160220A (es) 2016-07-22
KR20180059958A (ko) 2018-06-05
US20180016280A1 (en) 2018-01-18
MD20160063A2 (ro) 2016-11-30
MX2020010628A (es) 2020-10-22
BR112016010261A2 (https=) 2017-08-08
DOP2016000107A (es) 2016-06-15
SI3068405T1 (sl) 2019-08-30
US20250236623A1 (en) 2025-07-24
CA2928674C (en) 2018-10-02
US20170008897A1 (en) 2017-01-12
AU2017232039B2 (en) 2019-03-28
US9388208B2 (en) 2016-07-12
PT3068405T (pt) 2019-08-05
LT3068405T (lt) 2019-08-12
JP2018070658A (ja) 2018-05-10
JP2022088661A (ja) 2022-06-14
EA201792639A1 (ru) 2018-09-28
US20190055253A1 (en) 2019-02-21
DK3505173T3 (da) 2022-08-22
HRP20220920T1 (hr) 2022-10-28
EP4122932A1 (en) 2023-01-25
AU2017232039C1 (en) 2019-07-25
HRP20191303T1 (hr) 2019-10-18
SG11201603427XA (en) 2016-05-30
TR201910961T4 (tr) 2019-08-21
IL245324B (en) 2018-08-30
UA119050C2 (uk) 2019-04-25
KR102355881B1 (ko) 2022-01-25
EP3505173A1 (en) 2019-07-03
MY182986A (en) 2021-02-05
PT3505173T (pt) 2022-11-18
KR101864973B1 (ko) 2018-06-05
CA2928674A1 (en) 2015-05-14
JP7247155B2 (ja) 2023-03-28
MX2016006066A (es) 2016-08-12
JP2018021051A (ja) 2018-02-08
JP2020055855A (ja) 2020-04-09
AU2019204381A1 (en) 2019-07-11
AU2023202506A1 (en) 2023-05-11
US10059716B2 (en) 2018-08-28
NZ719592A (en) 2017-12-22
JP2026027391A (ja) 2026-02-18
ZA201603123B (en) 2019-08-28
MY197933A (en) 2023-07-25
PL3505173T3 (pl) 2022-10-17
KR20210046833A (ko) 2021-04-28
CN110003215B (zh) 2021-12-17
AU2019204381B2 (en) 2021-04-01
JP6234571B2 (ja) 2017-11-22
EA029712B1 (ru) 2018-05-31
EP3068405A1 (en) 2016-09-21
BR112016010261B1 (pt) 2022-02-08
KR102113705B1 (ko) 2020-05-21
MD4596B1 (ro) 2018-10-31
US10377761B2 (en) 2019-08-13
AU2017232039A1 (en) 2017-10-12
KR20160074011A (ko) 2016-06-27
LT3505173T (lt) 2022-10-10

Similar Documents

Publication Publication Date Title
HUE044960T2 (hu) Légúti szincíciális vírus okozta fertõzések kezelésében hasznos pirrolo-[1,2,F][1,2,4]triazinok
SG11202012656WA (en) Heterocyclic compounds useful in the treatment of disease
PL2852391T3 (pl) Układy do leczenia infekcji płuc
SI3019503T1 (sl) Policiklične karbamoilpiridonske spojine in njihova uporaba za zdravljenje HIV infekcij
BR112014017749A2 (pt) Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
PT2935303T (pt) 4'-fluoro-nucleósidos, 4'-fluoro-nucleótidos e seus análogos para o tratamento de hcv
LT3019499T (lt) Policikliniai karbamoilpiridono junginiai ir jų panaudojimas živ infekcijų gydymui
PL2970398T3 (pl) Białka f rsv przed fuzją i ich zastosowanie
LT2970123T (lt) Omekamtivo mekarbilo druska ir jos gamybos būdas
IL245101B (en) Derivatives of 1,4-cyclohexylamine and processes for their preparation
LT2945642T (lt) Faktoriaus 1 baltymas, skirtas naudoti ligų gydymui arba prevencijai
IL242163B (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
PL3071570T3 (pl) Pochodne 2,6-podstawionej puryny i ich zastosowanie w leczeniu zaburzeń proliferacyjnych
IL242293B (en) Bacteriophage therapy
LT3064498T (lt) Pirazolpirimidono arba piroltriazono dariniai, jų paruošimo būdas ir jų farmacinis panaudojimas
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
BR112016013524A2 (pt) concentrado de suspensão dispersivo em água e composição de tratamento de plantas compreendendo o mesmo
TH1501001789A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส
BR302013002174S1 (pt) "configuração aplicada em berço"
TH1501001885A (th) อนุพันธ์ไพโรโล [3,2-d] ไพริมิดีนสำหรับการบำบัดของการติดเชื้อไวรัสและโรคอื่นๆ